Rhenman & Partners Asset Management’s Epizyme, Inc EPZM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-265,000
Closed -$702K 96
2021
Q4
$702K Hold
265,000
0.05% 91
2021
Q3
$1.36M Hold
265,000
0.1% 90
2021
Q2
$2.2M Hold
265,000
0.15% 91
2021
Q1
$2.31M Hold
265,000
0.16% 91
2020
Q4
$2.88M Hold
265,000
0.23% 76
2020
Q3
$3.16M Hold
265,000
0.28% 71
2020
Q2
$4.26M Sell
265,000
-85,000
-24% -$1.48M 0.46% 68
2020
Q1
$5.43M Sell
350,000
-75,000
-18% -$1.61M 0.76% 50
2019
Q4
$10.5M Sell
425,000
-25,028
-6% -$372K 1.15% 36
2019
Q3
$4.64M Sell
450,028
-43,651
-9% -$551K 0.58% 58
2019
Q2
$6.2M Buy
493,679
+434,474
+734% +$5.59M 0.68% 54
2019
Q1
$734K Buy
+59,205
New +$662K 0.09% 75
2018
Q2
Sell
-181,291
Closed -$3.22M 92
2018
Q1
$3.22M Sell
181,291
-36,300
-17% -$613K 0.4% 63
2017
Q4
$2.73M Sell
217,591
-18,702
-8% -$272K 0.37% 68
2017
Q3
$4.5M Sell
236,293
-15,843
-6% -$242K 0.57% 61
2017
Q2
$3.81M Buy
+252,136
New +$3.81M 0.55% 65
2015
Q3
Sell
-131,785
Closed -$3.16M 99
2015
Q2
$3.16M Buy
+131,785
New +$2.54M 0.38% 79

Other funds holding EPZM

Rhenman & Partners Asset Management's EPZM Position: Q1 2022 in Review

Rhenman & Partners Asset Management sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 265,000 shares — an estimated $702K sold.

Rhenman & Partners Asset Management first reported a position in EPZM in Q2 2015 and held it in 17 quarters. The position peaked at $10.5M in Q4 2019. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • Rhenman & Partners Asset Management reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 265,000 Epizyme, Inc shares in Q1 2022, an estimated $702K.
  • Rhenman & Partners Asset Management first reported a position in Epizyme, Inc in Q2 2015 and held it in 17 quarters.
  • Rhenman & Partners Asset Management's Epizyme, Inc position peaked at $10.5M in Q4 2019.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2022, filed 13 May 2022.